Exact Sciences has acquired Paradigm Diagnostics and Viomics to extend its lab testing and research and development capabilities, the company announced recently.

According to a release, Paradigm offers a comprehensive genomic profiling test for patients with advanced, refractory, or recurrent cancer, allowing physicians to better understand a patient’s tumor profile and more effectively recommend targeted therapies or clinical trials. Viomics provides extensive sequencing capabilities and expertise in identifying unique biomarkers that indicate the presence of cancer in solid tissue and blood.

“The addition of these companies and their talented team members to Exact Sciences is another step forward in extending our leadership in advanced cancer diagnostics,” Exact Sciences CEO Kevin Conroy said in a statement. “Viomics’ research capabilities and the Paradigm therapy selection test and scalable clinical lab, combined with the powerful Exact Sciences commercial platform, allow us to provide patients with smarter, faster answers throughout the cancer continuum.”

Financial terms of the deal were not disclosed. Both companies will remain in Phoenix.